|
HY-P1240B-1mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240B-10mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240B-5mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240A-1mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1240A-10mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1240A-5mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-W539893-100mg
|
MedChemexpress LLC
|
NODAGA-tris(t-Bu ester) [CAS 1190101-34-8]
|
|
Cancer-programmed cell death
|
|
|
HY-126360-1g
|
MedChemexpress LLC
|
Oxazolone [CAS 15646-46-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-126360-5g
|
MedChemexpress LLC
|
Oxazolone [CAS 15646-46-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-126360-500mg
|
MedChemexpress LLC
|
Oxazolone [CAS 15646-46-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-126360-1mL
|
MedChemexpress LLC
|
Oxazolone [CAS 15646-46-5] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-Y0332C-100g
|
MedChemexpress LLC
|
Phosphoric acid (sodium hydrate),?99.0% [CAS 13472-35-0]
|
|
|
|
|
HY-138633-1mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-10 [CAS 2417370-49-9]
|
|
Cancer-programmed cell death
|
|
|
HY-138633-10mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-10 [CAS 2417370-49-9]
|
|
Cancer-programmed cell death
|
|
|
HY-138633-5mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-10 [CAS 2417370-49-9]
|
|
Cancer-programmed cell death
|
|
|
HY-138633-1mL
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-10 [CAS 2417370-49-9] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-138634-1mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-11
|
|
Cancer-programmed cell death
|
|
|
HY-138634-10mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-11
|
|
Cancer-programmed cell death
|
|
|
HY-138634-5mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-11
|
|
Cancer-programmed cell death
|
|
|
HY-138634-1mL
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-11 [CAS ] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-138635-1mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-12 [CAS 2417370-90-0]
|
|
Cancer-programmed cell death
|
|
|
HY-138635-10mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-12 [CAS 2417370-90-0]
|
|
Cancer-programmed cell death
|
|
|
HY-138635-5mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-12 [CAS 2417370-90-0]
|
|
Cancer-programmed cell death
|
|
|
HY-138635-1mL
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-12 [CAS 2417370-90-0] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-138632-1mg
|
MedChemexpress LLC
|
PROTAC BRD4 Degrader-9 [CAS 2417370-42-2]
|
|
Cancer-programmed cell death
|
|
